| Name | Title | Contact Details |
|---|
Alara is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Life Recovery Systems HD is a Kinnelon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BIÂN is a private members club built on the foundation of holistic wellness, vitality, and social well-being. In one dynamic, design-forward space, we weave Eastern and Western healing philosophies, mental health consultations, concierge medicine, holistic apothecary, extensive fitness, yoga and studio offerings, chef-driven artisanal food and beverage, innovative therapeutic modalities, luxurious spa and beauty services, and programming in our grand social gathering spaces.
Fresenius Medical Care is the world`s leading provider of products and services for people with chronic kidney failure. Around 2.8 M patients with this disease worldwide regularly undergo dialysis treatment. Dialysis is a vital blood cleansing procedure that substitutes the function of the kidney in case of kidney failure. We care for more than 300,000 patients in our global network of more than 3,500 dialysis clinics. At the same time, we operate ~ 40 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables. Our strategy is geared toward sustainable growth. We aim to continuously improve the quality of life of patients with kidney disease by offering innovative products and treatment concepts of the highest quality. Fresenius Medical Care`s corporate headquarters are in Bad Homburg v.d.H., Germany. The headquarters of North America are in Waltham, Massachusetts and the headquarters of Asia-Pacific are located in Hong Kong.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.